MYRIAD GENETICS INC. - COMMON STOCK

New Study Published in JCO Precision Oncology Shows Myriad Genetics' Prolaris Test Can Predict Benefit of Hormone Therapy Treatment in Men with Localized Prostate Cancer

16 май 2024 16:05:00 Источник Nasdaq GlobeNewswire

NetDania - New 12 months High: MYRIAD GENETICS INC. - COMMON STOCK

10 май 2024 09:45:09 Источник NetDania Notify

NetDania - New 12 months High: MYRIAD GENETICS INC. - COMMON STOCK

09 май 2024 09:49:28 Источник NetDania Notify

Myriad Genetics Reports Strong First Quarter 2024 Financial Results; Achieves 12% Revenue Growth Year-Over-Year; Significantly Improved Year-Over-Year Net Loss and Generated Positive Adjusted EBITDA

07 май 2024 16:05:00 Источник Nasdaq GlobeNewswire

Myriad Genetics Announces Reorganization of European Operations and Sale of EndoPredict Business

07 май 2024 09:00:00 Источник Nasdaq GlobeNewswire

Myriad Genetics to Release First Quarter 2024 Financial Results on May 7, 2024

30 апр 2024 16:05:00 Источник Nasdaq GlobeNewswire

Nearly Half of Americans Say They’ve Lost Time in Their Lives Due to Poor Mental Health, According to the GeneSight Mental Health Monitor

17 апр 2024 08:00:00 Источник Nasdaq GlobeNewswire

New Myriad Genetics Study Published in Prenatal Diagnosis Shows High Positive Predictive Value for 22q11.2 Microdeletion Syndrome Using Prequel® Prenatal Screen

16 апр 2024 09:15:00 Источник Nasdaq GlobeNewswire

Myriad Genetics Research Shows Reduction in Hospitalizations for Patients with Depression after GeneSight Testing

09 апр 2024 08:00:00 Источник Nasdaq GlobeNewswire

Myriad Genetics Announces Foundational Patent Granted for Molecular Residual Disease (MRD) with Early Priority Date

21 мар 2024 21:40:00 Источник Nasdaq GlobeNewswire

Myriad Genetics Announces Patent Granted for SneakPeek® Snap Device

20 мар 2024 16:05:00 Источник Nasdaq GlobeNewswire

Myriad Genetics Reports Strong Fourth Quarter and Full-Year 2023 Financial Results; Fourth Quarter Revenue of $197 Million and Full-Year Revenue of $753 Million Each Grew 11% Year-Over-Year; Delivered GAAP EPS of $(0.36) and Adjusted EPS of $0.04 in the Fourth Quarter 2023; Raising 2024 Revenue Guidance

27 фев 2024 16:05:01 Источник Nasdaq GlobeNewswire

Myriad Genetics and National Cancer Center Hospital East in Japan Collaborate on Pan-Cancer MRD Monitoring Clinical Trial, SCRUM-MONSTAR-SCREEN-3

27 фев 2024 09:15:00 Источник Nasdaq GlobeNewswire

Myriad Genetics to Release Fourth Quarter and Full Year 2023 Financial Results on February 27, 2024

21 фев 2024 16:05:00 Источник Nasdaq GlobeNewswire

Myriad Genetics Appoints Dallas Reed, MD, FACOG, FACMG as Principal Medical Advisor of Women’s Health

15 фев 2024 16:05:00 Источник Nasdaq GlobeNewswire

Myriad Genetics Completes Acquisition of Precise Tumor, Precise Liquid and Laboratory from Intermountain Precision Genomics

01 фев 2024 09:25:00 Источник Nasdaq GlobeNewswire

Myriad Genetics Names George Daneker Jr., MD, as President and Chief Clinical Officer of Oncology

30 янв 2024 17:00:00 Источник Nasdaq GlobeNewswire

Myriad Genetics to Acquire Precise Tumor, Precise Liquid and Laboratory from Intermountain Precision Genomics

18 янв 2024 18:10:00 Источник Nasdaq GlobeNewswire

Myriad Genetics Applauds New Germline Testing Guideline for Patients with Breast Cancer from ASCO-SSO

09 янв 2024 16:05:00 Источник Nasdaq GlobeNewswire

Myriad Genetics to Present at 42nd Annual J.P. Morgan Healthcare Conference

03 янв 2024 16:05:00 Источник Nasdaq GlobeNewswire